iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway Progressed

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway

Progressed Pipeline with New Preclinical Data and Scientific Presentations at Leading Industry Conferences

San Diego, California / February 10, 2026 / (GLOBE NEWSWIRE) / iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today reported financial results for the second quarter ended Dec. 31, 2025, and provided a corporate update on its progress.

"We have significantly advanced our preclinical pipeline programs - IBIO-610, our activin E antibody, and IBIO-600, our myostatin antibody - towards the start of human clinical trials by initiating CMC development and toxicology studies," said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. "Additionally, we recently completed a $26 million private placement financing with a highly respected biotech investor, strengthening our resources for pipeline progress and taking us one step closer to fulfilling our mission of reaching patients in need of an accessible, transformative therapy for obesity. The positive news positions us well to execute on our planned milestones and corporate priorities throughout 2026 and 2027."

Second Fiscal Quarter 2026 & Recent Corporate Updates:

No revenue was recognized for the three months ending December 31, 2025. Revenue of $0.2 million was recognized for the three months ending December 31, 2024.

Research and Development ("R&D") expenses for the three months ending December 31, 2025, and December 31, 2024, were $4.3 million and $1.9 million, respectively, an increase of approximately $2.4 million. The increase in R&D expenses is mainly due to increased spending on consultants and outside services supporting the Company's R&D efforts, including conducting the NHP studies and CMC activities, and an increase in personnel costs as a result of advancing research activities for the Company's IBIO-600 and IBIO-610 programs and other preclinical pipeline assets. The increase was partially offset by decreased spending on consumable supplies.

General and Administrative expenses for the three months ending December 31, 2025, and December 31, 2024, were approximately $5.2 million and $2.7 million, respectively, an increase of $2.5 million. The increase is primarily attributable to the impairment of the Company's indefinite lived intangible asset IBIO-101.

iBio held cash, cash equivalents and investments in debt securities of $52.7 million as of December 31, 2025. In addition, in January 2026, the Company received net proceeds of approximately $24.4 million from the PIPE financing extending the Company's cash runway into third quarter of fiscal year 2028.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding fulfilling iBio's mission of reaching patients in need of an accessible, transformative therapy for obesity; executing iBio's planned milestones and corporate priorities throughout 2026 and into 2027; the net proceeds of the private placement being used for the advancement of key preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs, while extending the Company's cash runway into third quarter of fiscal year 2028 and funding general corporate purposes; the potential of IBIO-610, a first-in-class Activin E antibody candidate, to have a human half-life of up to 100 days, supporting

potentially dosing as infrequent as twice per year; the completion of NHP, CMC, and toxicology studies for IBIO-610; the commencement of first human clinical trials for IBIO-610 in early calendar year 2027; the completion of toxicology studies for IBIO-600; the entering Phase1a clinical trials for IBIO-600 by the first half of calendar year 2026; the continuation of development efforts for the Company's bispecific myostatin activin A program and amylin candidates; the Company's ability to leverage AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases; iBio's ability to combine its proprietary 3D modeling with its innovative drug discovery platforms to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and iBio's ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the potential of IBIO-610, a first-in-class Activin E antibody candidate, to have a human half-life of up to 100 days, supporting potentially dosing as infrequent as twice per year; the ability of iBio to complete NHP, CMC, and toxicology studies for IBIO-610; the ability of iBio to commence first in human clinical trials for IBIO-610 by early calendar year 2027; the ability of iBio to complete toxicology studies for IBIO-600; the ability of iBio to enter Phase 1a clinical trials for IBIO-600 by the first half of calendar year 2026; iBio's ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio's ability to promote or commercialize its product candidates for specific indications; acceptance of iBio's product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio's filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Ignacio Guerrero-Ros, Ph.D., or David Schull

(858) 717-2310 or (646) 942-5604

iBio, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

iBio, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited; in thousands, except per share amounts)